Statement of Principles concerning polyarteritis nodosa No. 12 of 2011

Administered by Department of Veterans' Affairs

Legislation au F2010L03259 Not in force Legislative Instrument

Legislation content

 

 

REPATRIATION MEDICAL AUTHORITY

 

INSTRUMENT NO. 12 of 2011

 

VETERANS’ ENTITLEMENTS ACT 1986

MILITARY REHABILITATION AND COMPENSATION ACT 2004

 

EXPLANATORY NOTES FOR TABLING

 

 

  1. The Repatriation Medical Authority (the Authority), under subsection 196B(8) of the Veterans’ Entitlements Act 1986 (the VEA), revokes Instrument No. 158 of 1996, determined under subsection 196B(3) of the VEA concerning polyarteritis nodosa.

 

2.             The Authority is of the view that on the sound medical-scientific evidence available it is more probable than not that polyarteritis nodosa and death from polyarteritis nodosa can be related to particular kinds of service.  The Authority has therefore determined pursuant to subsection 196B(3) of the VEA a Statement of Principles, Instrument No. 12 of 2011 concerning polyarteritis nodosa.  This Instrument will in effect replace the revoked Statement of Principles.

 

3.             The provisions of the Military Rehabilitation and Compensation Act 2004 (the MRCA) relating to claims for compensation commenced on 1 July 2004.  Claims under section 319 of the MRCA for acceptance of liability for a service injury sustained, a service disease contracted or service death on or after 1 July 2004 are determined by the Military Rehabilitation and Compensation Commission by reference to Statements of Principles issued by the Authority pursuant to the VEA.

 

4.             The Statement of Principles sets out the factors that must exist, and which of those factors must be related to the following kinds of service rendered by a person:

 

 eligible war service (other than operational service) under the VEA;

 defence service (other than hazardous service) under the VEA;

 peacetime service under the MRCA,

 

before it can be said that, on the balance of probabilities, polyarteritis nodosa or death from polyarteritis nodosa is connected with the circumstances of that service.

 

5.             This Instrument results from an investigation notified by the Authority in the Government Notices Gazette of 25 June 2008 concerning polyarteritis nodosa in accordance with section 196G of the VEA.  The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.

 

6.             The contents of this Instrument are in similar terms as the revoked Instrument.  Comparing this Instrument and the revoked Instrument, the differences include:

 

  • adopting the latest revised Instrument format, which commenced in 2005;
  • deleting the ICD code from the Instrument header;
  • revising the definition of 'polyarteritis nodosa' in clause 3;
  • revising factor 6(a) concerning 'being infected with hepatitis B virus';
  • new factors 6(b) & 6(d) concerning 'being infected with human immunodeficiency virus';
  • new factor 6(c) concerning clinical worsening and 'being infected with hepatitis B virus';
  • new definitions of 'death from polyarteritis nodosa', 'ICD-10-AM code' and 'terminal event' in clause 9;
  • revising definition of 'relevant service' in clause 9;
  • deleting definitions of 'classic polyarteritis nodosa', 'evidence of infection with hepatitis B', 'ICD code' and 'microscopic polyangiitis'; and
  • specifying a date of effect for the Instrument in clause 11.

 

7.             Further changes to the format of the Instrument reflect the commencement of the MRCA and clarify that pursuant to subsection 196B(3A) of the VEA, the Statement of Principles has been determined for the purposes of both the VEA and the MRCA.

 

8.             Prior to determining this Instrument, the Authority advertised its intention to undertake an investigation in relation to polyarteritis nodosa in the Government Notices Gazette of 25 June 2008, and circulated a copy of the notice of intention to investigate to a wide range of organisations representing veterans, service personnel and their dependants.  The Authority invited submissions from the Repatriation Commission, organisations and persons referred to in section 196E of the VEA, and any person having expertise in the field.  An eligible person lodged submissions on three separate occasions for consideration by the Authority during the investigation.

 

9.             The determining of this Instrument finalises the investigation in relation to polyarteritis nodosa as advertised in the Government Notices Gazette of 25 June 2008. The investigation concerning polyarteritis nodosa has resulted in the determination of Statements of Principles concerning polyarteritis nodosa and also Statements of Principles concerning microscopic polyangiitis. Microscopic polyangiitis is now being classified as a separate disease.

 


10.         A list of references relating to the above condition is available to any person or organisation referred to in subsection 196E(1)(a) to (c) of the VEA.  Any such request must be made in writing to the Repatriation Medical Authority at the following address:

The Registrar

Repatriation Medical Authority Secretariat

GPO Box 1014

BRISBANE    QLD    4001

Overview

The Repatriation Medical Authority Instrument No. 12 of 2011, concerning polyarteritis nodosa, was enacted to address the problem of determining the connection between polyarteritis nodosa and military service, particularly in light of new medical-scientific evidence. This legislative instrument revokes the previous Instrument No. 158 of 1996 under the Veterans’ Entitlements Act 1986 (VEA) and the Military Rehabilitation and Compensation Act 2004 (MRCA), and establishes a new Statement of Principles. The Authority, acting under the VEA, determined that polyarteritis nodosa and death from this condition are more likely to be related to specific military services. The new instrument provides a framework for assessing claims for compensation related to polyarteritis nodosa, setting out the necessary factors and their connection to various types of military service. The Authority conducted an investigation and invited submissions from relevant organisations and individuals, culminating in the finalisation of this Instrument, which is applicable for both the VEA and the MRCA.

Scope and Application

The Repatriation Medical Authority Instrument No. 12 of 2011, concerning polyarteritis nodosa, applies to veterans and service personnel who have rendered eligible war service, defence service, or peacetime service as defined under the Veterans' Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004. This Instrument establishes the Statement of Principles that must be met for polyarteritis nodosa or death from polyarteritis nodosa to be connected with the service rendered, thereby affecting eligibility for compensation claims. The Instrument has a Commonwealth reach, impacting individuals and entities involved in veterans’ affairs across Australia. Exclusions or exemptions are not explicitly stated, but the Instrument's application is contingent on the specific factors outlined relating to the service and medical condition. The Instrument extends its application through the VEA and MRCA, with further clarifications and administrative adjustments made through subordinate instruments as necessary.

Key Provisions

The Repatriation Medical Authority (RMA) has revoked Instrument No. 158 of 1996 concerning polyarteritis nodosa, determined under subsection 196B(3) of the Veterans’ Entitlements Act 1986 (VEA) and has issued a new Instrument No. 12 of 2011. This new Instrument replaces the previous one, taking into account the sound medical-scientific evidence available, indicating that polyarteritis nodosa and death from polyarteritis nodosa can be related to specific kinds of service (section 2). The Statement of Principles set out in this Instrument outlines the factors that must exist, and which of those factors must be related to certain kinds of service, before it can be said that, on the balance of probabilities, polyarteritis nodosa or death from polyarteritis nodosa is connected with the circumstances of that service (section 4). The obligations imposed by this Instrument include the requirement for claims under section 319 of the Military Rehabilitation and Compensation Act 2004 (MRCA) for acceptance of liability for a service injury sustained, a service disease contracted or service death on or after 1 July 2004 to be determined by the Military Rehabilitation and Compensation Commission by reference to Statements of Principles issued by the Authority pursuant to the VEA (section 3). The Authority has advertised its intention to undertake an investigation in relation to polyarteritis nodosa, inviting submissions from the Repatriation Commission, organisations and persons referred to in section 196E of the VEA, and any person having expertise in the field (section 8). There are no specific offences, penalties, or civil/criminal consequences for breach mentioned in this Instrument. However, the Authority has the power to determine Statements of Principles concerning polyarteritis nodosa and other related conditions, and to revoke previous Instruments as necessary based on the sound medical-scientific evidence available (sections 2, 7, and 9). It is important for the parties and entities governed by this Act to adhere to the requirements and guidelines set out in the Instrument to ensure proper assessment and compensation for those affected by polyarteritis nodosa and related conditions.

Legal classification tags

Area of Law
Veterans' Affairs
Instrument
Instrument
Concepts
Definitions & Interpretation
Repeal & Amendment
Regulatory Standards

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.